G6PD Deficiency and Blood Donation
Individuals with G6PD deficiency can safely donate blood, and there is no evidence-based requirement to routinely screen blood donors for G6PD deficiency or to exclude G6PD-deficient donors from donation.
Current Practice and Evidence
The available evidence indicates that G6PD-deficient individuals are not routinely excluded from blood donation in most countries, including the United States. While G6PD deficiency is the most common human enzyme deficiency affecting approximately 35 million people globally 1, systematic screening of blood donors is not standard practice.
Safety for the Donor
G6PD-deficient individuals can donate blood without increased risk to themselves. A study of 101 hematopoietic stem cell donors found that 19% were G6PD-deficient, and these donors showed no difference in safety parameters, complication rates, or hemoglobin recovery compared to normal donors 2. The donation process itself does not expose G6PD-deficient donors to the oxidative stressors that typically trigger hemolysis in this condition.
Safety for Recipients
The evidence regarding recipient safety is more nuanced:
For most adult recipients: A systematic review found little evidence to suggest that G6PD-deficient individuals should be excluded from donating red blood cells for general adult transfusion 3. Recent research from China involving 1,028 blood donors (11.77% carrying G6PD deficiency) demonstrated that patients receiving transfusions from G6PD-deficient donors showed no significant differences in adverse reaction rates or hemoglobin elevation compared to recipients of normal donor blood 4.
For vulnerable populations: The evidence suggests potential concerns for specific at-risk groups:
Neonates and premature infants: Multiple studies reported abnormal rises in total serum bilirubin in infants transfused with G6PD-deficient blood, occurring from 6 to 60 hours post-transfusion. Their immature hepatic function makes them less able to handle excess bilirubin loads 3.
Chronically transfused patients: Patients requiring repeated transfusions may be at higher risk, though definitive evidence is limited 3, 5.
Storage Considerations
G6PD-deficient red blood cells undergo accelerated deterioration during refrigerated storage. Research shows that over 14 days of storage, G6PD-deficient blood units experience:
- Significant decreases in hemoglobin and red blood cell count
- Increased mean corpuscular volume and red cell distribution width
- Progressive loss of cellular membrane homeostatic mechanisms 6
This oxidative damage accumulation during storage adversely affects transfusion efficacy more severely in G6PD-deficient units 5.
Clinical Recommendations
For blood donation centers:
- Routine screening for G6PD deficiency is not required for general blood donation
- Consider implementing screening protocols if your recipient population includes high proportions of neonates or chronically transfused patients
- Document G6PD status when known to allow selective use for appropriate recipients
For transfusion services:
- Use standard donor blood for adult recipients without special restrictions
- Consider requesting G6PD-normal blood for:
- Premature neonates and infants
- Patients requiring chronic transfusion support
- Patients receiving oxidative medications or with concurrent infections that could trigger hemolysis
For potential donors with known G6PD deficiency:
- You can safely donate blood
- Avoid oxidative stressors (certain medications, infections, fava beans) around the time of donation as you would normally
- The donation process itself poses no special risk
Important Caveats
The evidence base has significant limitations: studies use non-standardized methods to categorize G6PD deficiency, sample sizes are often small, and methodological quality varies 3. The prevalence of G6PD deficiency varies dramatically by geographic region (up to 35% in some tropical and subtropical areas) 6, 7, which may influence local policy decisions.
Despite theoretical concerns about transfusing G6PD-deficient blood, particularly to vulnerable populations, these concerns have not led to changes in clinical practice in most countries, including the United States 5. The co-inheritance of G6PD deficiency with other conditions like sickle cell trait (6% prevalence in one study) adds complexity but does not currently warrant routine screening 7.